Dermata Therapeutics commences treatment in Phase 2 atopic dermatitis study

Biotechnology company Dermata Therapeutics has announced the dosing of its first patient in a Phase 2 atopic dermatitis study with its lead compound DMT210.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news